Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
Chuah S, Lee J, Song Y, Kim HD, Wasser M, Kaya NA, Bang K, Lee YJ, Jeon SH, Suthen S, A'Azman S, Gien G, Lim CJ, Chua C, Hazirah SN, Lee HK, Lim JQ, Lim TKH, Yeong J, Chen J, Shin EC, Albani S, Zhai W, Yoo C, Liu H, Choo SP, Tai D, Chew V. Chuah S, et al. Among authors: yeong j. J Hepatol. 2022 Sep;77(3):683-694. doi: 10.1016/j.jhep.2022.03.039. Epub 2022 Apr 15. J Hepatol. 2022. PMID: 35430299 Free article.
Expression of CD38 on Macrophages Predicts Improved Prognosis in Hepatocellular Carcinoma.
Lam JH, Ng HHM, Lim CJ, Sim XN, Malavasi F, Li H, Loh JJH, Sabai K, Kim JK, Ong CCH, Loh T, Leow WQ, Choo SP, Toh HC, Lee SY, Chan CY, Chew V, Lim TS, Yeong J, Lim TKH. Lam JH, et al. Among authors: yeong j. Front Immunol. 2019 Sep 4;10:2093. doi: 10.3389/fimmu.2019.02093. eCollection 2019. Front Immunol. 2019. PMID: 31552039 Free PMC article.
Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma.
Ng HHM, Lee RY, Goh S, Tay ISY, Lim X, Lee B, Chew V, Li H, Tan B, Lim S, Lim JCT, Au B, Loh JJH, Saraf S, Connolly JE, Loh T, Leow WQ, Lee JJX, Toh HC, Malavasi F, Lee SY, Chow P, Newell EW, Choo SP, Tai D, Yeong J, Lim TKH. Ng HHM, et al. Among authors: yeong j. J Immunother Cancer. 2020 Aug;8(2):e000987. doi: 10.1136/jitc-2020-000987. J Immunother Cancer. 2020. PMID: 32847986 Free PMC article.
Clinicopathologic features, tumor immune microenvironment and genomic landscape of Epstein-Barr virus-associated intrahepatic cholangiocarcinoma.
Huang YH, Zhang CZ, Huang QS, Yeong J, Wang F, Yang X, He YF, Zhang XL, Zhang H, Chen SL, Zheng YL, Deng R, Lin CS, Yang MM, Li Y, Jiang C, Kin-Wah Lee T, Ma S, Zeng MS, Yun JP. Huang YH, et al. Among authors: yeong j. J Hepatol. 2021 Apr;74(4):838-849. doi: 10.1016/j.jhep.2020.10.037. Epub 2020 Nov 17. J Hepatol. 2021. PMID: 33212090 Free article.
Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ, Nguyen PHD, Wasser M, Kumar P, Lee YH, Nasir NJM, Chua C, Lai L, Hazirah SN, Loh JJH, Khor LY, Yeong J, Lim TKH, Low AWX, Albani S, Chong TW, Chew V. Lim CJ, et al. Among authors: yeong j. Front Immunol. 2021 Jan 29;11:615091. doi: 10.3389/fimmu.2020.615091. eCollection 2020. Front Immunol. 2021. PMID: 33584702 Free PMC article.
Non-terminally exhausted tumor-resident memory HBV-specific T cell responses correlate with relapse-free survival in hepatocellular carcinoma.
Cheng Y, Gunasegaran B, Singh HD, Dutertre CA, Loh CY, Lim JQ, Crawford JC, Lee HK, Zhang X, Lee B, Becht E, Lim WJ, Yeong J, Chan CY, Chung A, Goh BKP, Chow PKH, Chan JKY, Ginhoux F, Tai D, Chen J, Lim SG, Zhai W, Choo SP, Newell EW. Cheng Y, et al. Among authors: yeong j. Immunity. 2021 Aug 10;54(8):1825-1840.e7. doi: 10.1016/j.immuni.2021.06.013. Epub 2021 Jul 15. Immunity. 2021. PMID: 34270940 Free article.
134 results